These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1522 related items for PubMed ID: 30768123

  • 1. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW.
    J Crohns Colitis; 2019 Sep 19; 13(9):1111-1120. PubMed ID: 30768123
    [Abstract] [Full Text] [Related]

  • 2. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.
    Aliment Pharmacol Ther; 2016 Dec 19; 44(11-12):1199-1212. PubMed ID: 27714831
    [Abstract] [Full Text] [Related]

  • 3. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç, Yeşil B, Bacaksız F, Arı D, Gökbulut V, Yüksel M, Özderin Özin Y, Kayaçetin E.
    Turk J Gastroenterol; 2022 Oct 19; 33(10):831-837. PubMed ID: 35946879
    [Abstract] [Full Text] [Related]

  • 4. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, GETECCU study group.
    Aliment Pharmacol Ther; 2018 Oct 19; 48(8):839-851. PubMed ID: 30281832
    [Abstract] [Full Text] [Related]

  • 5. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
    Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W.
    Eur J Intern Med; 2019 Aug 19; 66():85-91. PubMed ID: 31208827
    [Abstract] [Full Text] [Related]

  • 6. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, SWIBREG Vedolizumab Study Group, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J.
    Scand J Gastroenterol; 2017 Aug 19; 52(6-7):722-729. PubMed ID: 28362144
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.
    J Crohns Colitis; 2017 Aug 01; 11(8):921-929. PubMed ID: 28333288
    [Abstract] [Full Text] [Related]

  • 12. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
    Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.
    Scand J Gastroenterol; 2018 Feb 01; 53(2):158-167. PubMed ID: 29258369
    [Abstract] [Full Text] [Related]

  • 13. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
    Cohen RD, Bhayat F, Blake A, Travis S.
    J Crohns Colitis; 2020 Feb 10; 14(2):192-204. PubMed ID: 31504340
    [Abstract] [Full Text] [Related]

  • 14. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M, Beltrán B, Maroto N, Navarro-Cortés P, Boscá-Watts M, Ferrer-Bradley I, García-Morales N, Sáez-González E, Hinojosa J, Mínguez M, Nos P.
    Gastroenterol Hepatol; 2018 Nov 10; 41(9):535-543. PubMed ID: 30031573
    [Abstract] [Full Text] [Related]

  • 15. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F.
    United European Gastroenterol J; 2021 Apr 10; 9(3):398-406. PubMed ID: 33203339
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.